At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Bortezomib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of the Combination of Subcutaneous (SQ) Bortezomib and Pegylated Liposomal Doxorubicin (PLD or Doxil or LipoDox) for the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML)
In Brief
A Phase 2 clinical trial evaluating Bortezomib and Doxil for Acute Myelogenous Leukemia. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartDec 2012
Primary CompletionMay 2019
TodayJul 2026
First PostedNov 29, 2012
Enrollment StartDec 19, 2012
Primary CompletionMay 20, 2019
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 13.6 years ago
Interventions
Bortezomibdrug
Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
Doxildrug
Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.